Maalox suspension 15ml 30 pcs pack.

Description

Composition
Active substance:
15 ml of suspension contains: magnesium hydroxide (in gel form) – 600.00 mg; aluminum hydroxide (in gel form) – 525,00 mg.
Excipients:
Concentrated hydrochloric acid, citric acid monohydrate, peppermint leaf oil, mannitol, metilparagidroksi- benzoate, propyl parahydroxybenzoate, sodium saccharinate, sorbitol (70%), hydrogen peroxide (30%), purified water.
Description:
White, or almost white, milky liquid with mint odor.
Product form:
Oral suspension bag (sachet), 15 ml. 15 ml of the formulation was put in bags (sachet), a paper / aluminum foil laminated with polyethylene. 30 bags (sachets) together with instructions for use placed in a cardboard box.
Contraindications
Severe renal insufficiency. Hypersensitivity to the active substances and other ingredients. Deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption (due to the presence of sorbitol in the composition of the drug). Children and adolescents under 15 years. Hypophosphatemia.
Carefully
Aluminum hydroxide may cause constipation, overdose magnesium salts can lead to the weakening of the intestinal peristalsis; in patients at high risk (patients with renal insufficiency, elderly patients), high doses of the drug can cause or exacerbate bowel obstruction and ileus. Aluminum hydroxide is poorly absorbed in the gastrointestinal tract, so in patients with normal renal function, systemic exposure is rare. Prolonged treatment, use of excessive doses or the use of normal doses for admission low background phosphate from food can lead to phosphate deficiency (due to binding to aluminum phosphate) which is accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia. Treatment of patients at risk of developing a phosphate deficiency or prolonged use of the drug should be carried out under medical supervision. If the kidney function (while taking the drug Maaloks® such patients may increase the plasma concentrations of magnesium and aluminum, and long-term use of the drug at high doses Maaloks®, including in high therapeutic doses may encephalopathy, dementia, microcytic anemia or aggravation of osteomalacia caused by dialysis). In patients with porphyria undergoing hemodialysis. During pregnancy and lactation (cm. “Apply during pregnancy and lactation”). In Alzheimer’s disease.
Indications
Gastric ulcer and duodenal ulcer in the acute phase. Acute gastro, chronic gastroduodenitis with normal or elevated secretion in the acute phase. Hiatal hernia, reflux esophagitis. Dyspepsia, or discomfort such as epigastric pain, heartburn, acid regurgitation after errors in the diet, excessive consumption of ethanol, coffee, nicotine etc. Dyspepsia, or discomfort such as epigastric pain, heartburn, acid regurgitation resulting from use of certain drugs (non-steroidal anti-inflammatory drugs, steroids, etc..) And their prevention.
Interaction with other drugs
With quinidine: while the use of quinidine may increase serum concentrations of quinidine and development quinidine overdose.
Since blockers of H2-histamine receptors, propranolol, atenolol, cefdinir, cefpodoxime, metoprolol, chloroquine, prostacyclin diflunisalom, digoxin, bisphosphonates, ethambutol, isoniazid, fluoroquinolones, sodium fluoride, glucocorticosteroids (described for prednisolone and dexamethasone), indomethacin, ketoconazole, lincosamides , phenothiazine antipsychotics, penicillamine, rosuvastatin, iron salts, levothyroxine: while receiving with the drug absorption is reduced Maaloks® above n eparatov in the gastrointestinal tract. In the case of a 2-hour interval between administration of these drugs and drug Maaloks® and 4-hour interval between the reception and Maaloks® fluoroquinolone drug in the majority of cases this undesirable interaction may be avoided.
With polystyrenesulfonate (kayeksalatom) When combined with the drug Maaloks® polystyrenesulfonate (kayeksalatom) should be careful because of the possible risk of reducing the effectiveness of the binding resin and potassium of metabolic alkalosis in patients with renal failure (for magnesium hydroxide and aluminum hydroxide), and intestinal obstruction ( aluminum hydroxide)
Citrate: the combination of aluminum hydroxide with citrate may increase the plasma concentrations of aluminum, especially in patients with renal insufficiency.
Overdose
Symptoms of acute overdose combination of aluminum hydroxide and magnesium salts include diarrhea, abdominal pain and vomiting. In patients at risk of high doses of the drug can cause or exacerbate bowel obstruction or ileus (see. Section ”
Carefully “)
Treatment of Aluminum and magnesium are excreted in the urine. Treatment of acute overdose carried out using a replenishment liquid losses and forced diuresis. Patients with kidney failure need to hemodialysis or peritoneal dialysis.
pharmachologic effect
Pharmacological group:
Antacid.
Pharmacodynamics:
Aluminum hydroxide and magnesium hydroxide neutralized free hydrochloric acid of the gastric juice without causing secondary hypersecretion. In addition, increasing the pH of the gastric juice when receiving Maaloks® drug reduces the pepsin activity in gastric juice. The drug has also absorbent and protective action, which decreases due to influence of disturbing factors on the mucosa of the esophagus and stomach.
Pharmacokinetics:
Magnesium hydroxide and aluminum hydroxide antacids are considered topical. Due to the low absorption does not have a systemic action.
Pregnancy and breast-feeding
Pregnancy: the animals received a clear indication of the presence of teratogenic effects of aluminum hydroxide and magnesium hydroxide. At the moment, did not reveal any specific teratogenic effects when using the drug Maaloks® during pregnancy, however, due to insufficient clinical experience with its use during pregnancy is possible only if the potential benefits of its application to the mother justifies the potential risk to the fetus .
Lactation: using as recommended by the absorption of magnesium hydroxide and aluminum salts in the mother combinations is limited, so the drug Maaloks® found compatible with breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
In compliance with the recommended dosing regimen side effects are rare.
To indicate the incidence of undesirable side effects, use the following classification of the World Health Organization: infrequent:> 0.1% and
Disorders of immune system: unknown frequency: hypersensitivity reactions such as itching, urticaria, angioedema, and anaphylaxis.
Disorders of the gastrointestinal tract: Uncommon: diarrhea, constipation.
Metabolic and Nutritional: unknown frequency: gipermagniemiya, giperalyuminemiya, hypophosphatemia (prolonged treatment or high doses, or dosage units upon receipt of the low content of phosphate in the food) which could lead to increased bone resorption, hypercalciuria, osteomalacia.
special instructions
If during the treatment of symptoms of the gastrointestinal tract are preserved for more than 10 days or deterioration is observed, it is necessary to clarify the diagnosis and to carry out the correction of medical measures. Caution must be a 2-hour interval between the application of the drug and other drugs Maaloks® and 4-hour interval between drug intake Maaloks® and fluoroquinolones (see. “Interaction with other drugs”). Despite the fact that the drug is available without a prescription, before use of the drug during pregnancy and lactation (breastfeeding), as well as in adolescents and patients with renal and mild to moderate severity failure are advised to consult with a physician. long destination Maaloks® formulation should be avoided in renal function. Maaloks® when administering the drug to patients with renal insufficiency mild to moderate severity must be carefully controlled plasma concentrations of aluminum and magnesium, and in the case of increasing the use of the preparation should be discontinued immediately. Algeldrat low phosphate content in the diet may lead to deficiency of phosphorus in the body. Therefore, when it is applied, particularly long, should ensure adequate intake of dietary phosphate.
Effects on ability to drive vehicles and operate machinery
The drug does not affect the ability to drive vehicles and operate machinery.
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
The drug is intended for oral use only by persons older than 15 years. Before applying the suspension in the bag should be homogenized, carefully stretching it between his fingers. The contents of the bag taken undissolved. Maaloks® ingest one sachet with a suspension (15 mL) was typically in 1-2 hours after meals and at bedtime, and in the event of epigastric pain and heartburn. The daily dose should not exceed 6 sachets instruction on use of the drug for medical use Maaloks® (90 ml suspension per day). When reflux esophagitis drug taking 30-60 minutes after eating. In gastric ulcer drug is taken 30 minutes before meals. The course of treatment should not exceed 2-3 months. If episodic application (e.g., discomfort after errors in the diet) – by taking 15 ml dose
C Patients renal dysfunction
Avoid the use of the drug in high doses and / or for a long time (see. The section ”
Carefully “).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist